Price-transparency regulations would significantly reduce U.S. healthcare costs

What's this about?

People disagree about whether clear health prices would cut U.S. health costs by a lot.

The facts show that price info may help in some cases, but not across the whole country.

What supporters say

• Clear prices can lower costs when people can shop around for planned care and choose cheaper care.
• Big price gaps between care sites leave room for buyers to save money by choosing lower-cost care.

What critics say

• Many listed prices leave out key facts or seem too hard for people to use.
• Clear prices alone have not shown big cuts in total U.S. health spending.

How to read this

The number of points on each side does not show which side is right; strong proof matters more.

The bottom line

Clear prices may help patients, firms, and health plans find lower-cost care in some cases.

But strong proof does not show that price rules alone would greatly cut health costs nationwide.

The claim is that requiring hospitals and doctors to publish their prices would significantly lower healthcare costs across the United States. The evidence suggests a narrower conclusion: price transparency can help in some situations, but disclosure alone has not been shown to produce large nationwide savings.

The case for

Price information can reduce spending when patients, employers or insurers can compare providers and have a real reason to choose a cheaper option. This is most likely for “shoppable” services, such as planned procedures, where patients have time to compare prices and several providers are available.

Research on reference-pricing programs supports this possibility. When people receive usable price information alongside financial incentives to avoid expensive providers, spending can fall for some shoppable services. 1 But these studies do not show that publishing prices alone caused the savings. The results reflect a combination of information, incentives and the ability to switch providers.

There is also a large potential opportunity. Hospital prices vary widely between providers and markets, according to RAND analyses. That variation means purchasers could potentially save money by directing care toward lower-priced providers or by using competing prices in negotiations. 2 The size of the gap shows that savings may be available, but it does not prove that transparency rules will capture them.

Price information may also help individual patients, even without reducing national spending. A patient who can identify a lower-cost provider could avoid an unexpectedly expensive bill or make a more affordable choice. These benefits could be meaningful for particular patients and employers, even if they remain too limited to change overall U.S. healthcare spending.

The case against

The strongest evidence so far does not show that transparency tools substantially reduce total healthcare spending nationwide. A systematic review found mixed results across studies. Some interventions changed consumer choices or provider prices, but broad reductions in overall spending remained limited and inconsistent. 3 The evidence map highlights both the variety of outcomes and the lack of an established nationwide spending effect (see Figure 1).

One problem is that many patients do not use price tools, or cannot act on the information they find. Referrals, insurance networks, urgent treatment and uncertainty about quality can leave patients with little practical choice. Even when lower-priced alternatives exist, switching may be difficult or impossible.

The information itself is often not ready for meaningful comparison. Assessments have found incomplete, inaccurate or noncompliant reporting by providers. Studies of transparency files have also found that prices can be difficult to locate, understand and compare. 4 Nominal coverage, in other words, does not necessarily provide patients or purchasers with usable prices (see Figure 3).

Market structure creates another limit. In concentrated healthcare markets, patients may face few alternatives and weak incentives to shop. Publicly revealing prices could even have an ambiguous effect: providers might move toward higher observed prices rather than compete them downward. The impact depends on accurate data, consumer and employer incentives, genuine provider choice and the kind of care involved.

The bottom line

The evidence does not support high confidence that price-disclosure regulations alone would significantly reduce overall U.S. healthcare costs. It does support a more limited conclusion: transparency can produce targeted savings when prices are accurate and easy to use, services are shoppable, and buyers have financial incentives and real alternatives.

The case against the broad claim is stronger than the case for it. Evidence for savings is credible but conditional, while systematic reviews have not established a large national reduction from disclosure by itself. The main uncertainty is whether policymakers can achieve accurate, usable reporting and create competitive purchasing conditions at a national scale.